You are here

  • Home
  • Archive
  • Volume 53, Issue 10
  • CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial

Article Text

Article menu
Download PDFPDF
Inflammatory bowel disease
CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial
  1. W J Sandborn1,
  2. B G Feagan2,
  3. G Radford-Smith3,
  4. A Kovacs4,
  5. R Enns5,
  6. A Innes6,
  7. J Patel6
  1. 1Mayo Clinic, Rochester, Minnesota, USA
  2. 2University of Western Ontario, London, Ontario, Canada
  3. 3Royal Brisbane Hospital, Herston, Queensland, Australia
  4. 4Peterfy Hospital, Budapest, Hungary
  5. 5St Paul’s Hospital, University of British Colombia, Vancouver, British Columbia, Canada
  6. 6Celltech Research and Development, Slough, UK
  1. Correspondence to:
    Dr W J Sandborn
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; sandborn.williammayo.edu

Abstract

Background: Targeting tumour necrosis factor α (TNF-α) has demonstrated efficacy in Crohn’s disease.

Aim: To evaluate CDP571, a humanised antibody to TNF-α, for treating active Crohn’s disease.

Patients: A total of 396 patients with moderate to severe Crohn’s disease.

Methods: In a 28 week, randomised, double blind, placebo controlled trial, patients received intravenous CDP571 (10 mg/kg) or placebo every eight weeks to week 24. The primary outcome measure was clinical response (a decrease in the Crohn’s disease activity index (CDAI) to ⩾100 points or remission (CDAI score ⩽150 points)) at week 28. A secondary outcome measure was clinical response (using the same definition) at week 2.

Results: Clinical response occurred at week 28 in 80/263 (30.4%) CDP571 patients and 31/132 (23.5%) placebo patients (p = 0.102). Clinical response at week 2 occurred in 90/263 (34.2%) CDP571 patients and 28/132 (21.2%) placebo patients (p = 0.011). Post hoc exploratory subgroup analysis of 159 patients with baseline C reactive protein (CRP) ⩾10 mg/l demonstrated significant differences between CDP571 and placebo in clinical response rates at weeks 2 (CDP571, 50/101 (49.5%); placebo, 9/58 (15.5%); p<0.001) and 28 (CDP571, 29/101 (28.7%); placebo, 7/58 (12.1%); p = 0.018). Adverse events occurred at similar frequencies in both treatment groups.

Conclusions: CDP571 is modestly effective for short but not long term treatment of unselected patients with moderate to severe Crohn’s disease. The clinical relevance of this short term effect is unclear. Post hoc analysis suggests both short and long term efficacy of CDP571 in patients with elevated baseline CRP (⩾10 mg/l). CDP571 is well tolerated.

  • CDAI, Crohn’s disease activity index
  • CDR, complementarity determining region
  • CRP, C reactive protein
  • HACA, human antichimeric antibody
  • IBDQ, inflammatory bowel disease questionnaire
  • ITT, intention to treat
  • TNF-α, tumour necrosis factor α
  • monoclonal antibody
  • CDP571
  • Crohn’s disease
  • tumour necrosis factor α
  • inflammatory bowel disease
  • tumour necrosis factor

https://doi.org/10.1136/gut.2003.035253

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Conflicts of interest: W Sandborn and B Feagan have served as consultants for Celltech. A Innes is an employee of Celltech. J Patel is a former employee of Celltech.